3.8 (PMOD Technologies Ltd, Zurich, Switzerland)
Antibody formation against Sermorelin can theoretically occur with chronic use, potentially reducing efficacy, though clinical significance appears limited
Tesamorelin Peptide Regulatory Status in Canada Health Canada Approval Status (Egrifta and Egrifta SV) Tesamorelin is the active ingredient in Egrifta, an approved prescription drug product authorized by Health Canada under a Notice of Compliance issued April 29, 2014, to Theratechnologies Inc
After youve reconstituted the peptide, keep the solution at 4C and use it promptly
According to Cleveland Clinic, estrogen causes water retention, while estrogen and progesterone can both cause intestinal gas through their impacts on how food moves through the digestive system